See Supplemental Patient Information
- Blood dyscrasias, some with fatal outcomes, have been reported with methsuximide use. Observe patients for signs/symptoms of infection such as sore throat, fever; measure blood counts regularly
- LFT and urinalysis should be performed periodically for all patients receiving methsuximide
- Cases of systemic lupus erythematosus have been reported during therapy
- Monitor patients receiving any antiepileptic drugs, including methsuximide, for the emergence/worsening of depression, suicidality, and/or unusual changes in mood or behavior. Increased risk of suicidal thoughts and behavior was noted as early as 7 days after initiation of therapy, and persisted for the duration of treatment assessed (24 wks in most clinical trials)
- The relative risk for suicidal thoughts or behavior was higher for epilepsy as compared to psychiatric or other conditions in clinical trials, but the absolute risk differences were same for epilepsy and psychiatric indications
- Advise families and caregivers about the need to closely monitor for the emergence or worsening of the signs/symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, or thoughts about self-harm and report such symptoms immediately to healthcare providers
- Methsuximide may be associated with increased incidence of birth defects. Do not discontinue therapy in patients with major seizures due to the chances of precipitating status epilepticus with attendant hypoxia and threat to life. The risks and benefits of methsuximide therapy should be weighed while treating epileptic women of childbearing potential
- Abrupt withdrawal of the drug may precipitate absence (petit mal) status; proceed slowly when increasing or decreasing the dose
- Withdraw the drug slowly on appearance of unusual depression, aggressiveness, or other behavioral alterations
- When used alone in mixed types of epilepsy, methsuximide may increase the frequency of grand mal seizures in some patients
- Since methsuximide may interact with concomitantly administered antiepileptic drugs, periodic serum level determinations of these drugs may be required
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- History of depression
Supplemental Patient Information
- Caution patients to refrain from performing potentially hazardous activities such as driving a motor vehicle or other tasks requiring alertness, as the drug may impair the mental and/or physical abilities necessary for performing such tasks
- Advise patients to promptly contact their physician if they develop any signs or symptoms suggestive of infection such as sore throat and fever
Pregnancy Category:C
Breastfeeding: Safety unknown.
Pricing data from www.DrugStore.com in U.S.A.
- Celontin 300 MG CAPS [Bottle] (PFIZER U.S.)
30 mg = $59.99
90 mg = $179.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Celontin 150 MG Oral Capsule
Ingredient(s): Methsuximide
Imprint: 150;mg;PD537
Color(s): Yellow
Shape: Capsule
Size (mm): 16.00
Score: 1
Inactive Ingredient(s): silicon dioxide / d&c yellow no. 10 / fd&c yellow no. 6 / gelatin / sodium lauryl sulfate
Drug Label Author:
Parke-Davis Div of Pfizer Inc
DEA Schedule:
Non-Scheduled
Drug Name: Celontin 300 MG Oral Capsule
Ingredient(s): Methsuximide
Imprint: 300;mg;PD525
Color(s): Yellow
Shape: Capsule
Size (mm): 19.00
Score: 1
Inactive Ingredient(s): silicon dioxide / d&c yellow no. 10 / fd&c yellow no. 6 / gelatin / sodium lauryl sulfate
Drug Label Author:
Parke-Davis Div of Pfizer Inc
DEA Schedule:
Non-Scheduled
